Galimedix Therapeutics presents new scientific data showing promising neuroprotective effects of GAL-201 for the treatment of Alzheimer’s disease at AD/PD™ 2024
08 mars 2024 04h00 HE
|
Galimedix Therapeutics, Inc.
GAL-201 specifically targets and binds to misfolded Aβ monomers, preventing their aggregation to toxic Aβ oligomers and protofibrilsAs a consequence, consistent beneficial effects have been...
Théa Open Innovation and Galimedix announce strategic partnership to develop and commercialize GAL-101, a Phase 2/3-ready small molecule, to treat ophthalmic indications with high unmet medical need
29 mars 2023 08h00 HE
|
Galimedix Therapeutics, Inc.
Galimedix eligible for upfront payment plus various success-based milestone payments and royalties on future net salesEquity investment by Théa Open Innovation into Galimedix supports further...
Galimedix Therapeutics, Inc.’s GAL-101 Gains from Target Validation by Positive Phase 3 Results of Biogen’s Aducanumab
29 oct. 2019 08h00 HE
|
Galimedix Therapeutics, Inc.
KENSINGTON, Md., Oct. 29, 2019 (GLOBE NEWSWIRE) -- Galimedix Therapeutics, Inc., an emerging leader in the development of new solutions for neurodegenerative diseases of the retina and the brain,...
Galimedix Therapeutics, Inc. To Present at the BIO Investor Summit
21 oct. 2019 09h45 HE
|
Galimedix Therapeutics, Inc.
KENSINGTON, Md. and SHORASHIM, Israel, Oct. 21, 2019 (GLOBE NEWSWIRE) -- Galimedix Therapeutics, Inc., an emerging leader in the development of new solutions for neurodegenerative diseases of the...
Galimedix Therapeutics, Inc. Appoints Recognized Industry Veteran, Alexander Gebauer, M.D., Ph.D., as Executive Chairman
21 oct. 2019 08h30 HE
|
Galimedix Therapeutics, Inc.
KENSINGTON, Md. and SHORASHIM, Israel, Oct. 21, 2019 (GLOBE NEWSWIRE) -- Galimedix Therapeutics, Inc., an emerging leader in the development of new solutions for neurodegenerative diseases of the...
Galimedix Therapeutics, Inc. To Present at Ophthalmology Innovation Summit During the American Academy of Ophthalmology Meeting
08 oct. 2019 09h35 HE
|
Galimedix
KENSINGTON, Md. and SHORASHIM, Israel , Oct. 08, 2019 (GLOBE NEWSWIRE) -- Galimedix Therapeutics, Inc., which is developing new solutions for neurodegenerative diseases of the retina and the brain,...
Preclinical Studies Demonstrate Galimedix Therapeutics’ Investigational Compound GAL-101 Shows Neuroprotective Effect from Toxic Amyloid-Beta in Dry AMD and Glaucoma Models
08 mai 2019 08h00 HE
|
Galimedix
KENSINGTON, Md. and SHORASHIM, Israel, May 08, 2019 (GLOBE NEWSWIRE) -- Galimedix Therapeutics, which is developing new solutions for ophthalmic and neurodegenerative diseases, today presented data...
Galimedix, Inc. Appoints Renowned Industry Veteran and Innovator in the Field of Ophthalmology Thomas Hohman, Ph.D. to Board of Directors
06 mai 2019 07h00 HE
|
Galimedix
KENSINGTON, Md. and SHORASHIM, Israel, May 06, 2019 (GLOBE NEWSWIRE) -- Galimedix Therapeutics, which is developing new solutions for ophthalmic and neurodegenerative diseases, today announces the...
Galimedix Therapeutics to Present at the BIO CEO & Investor Conference
11 févr. 2019 08h30 HE
|
Galimedix
KENSINGTON, Md. and SHORASHIM, Israel, Feb. 11, 2019 (GLOBE NEWSWIRE) -- Galimedix Therapeutics, which is developing new solutions for ophthalmic and neurodegenerative diseases, today announced...
Galimedix Therapeutics Presents Data Showing Safety, Tolerability and Potential for Efficacy of Its Investigational Eyedrops Containing GAL-101 at Glaucoma 360 Conference
06 févr. 2019 09h35 HE
|
Galimedix
KENSINGTON, Md. and SHORASHIM, Israel, Feb. 06, 2019 (GLOBE NEWSWIRE) -- Galimedix Therapeutics, which is developing new solutions for ophthalmic and neurodegenerative diseases, presented an...